Drug Price Trends for NDC 72511-0760

Average Pharmacy Cost for 72511-0760

Drug Name	NDC	Price/Unit ($)	Unit	Date
REPATHA 140 MG/ML SURECLICK	72511-0760-02	281.94923	ML	2026-01-07
REPATHA 140 MG/ML SURECLICK	72511-0760-02	276.41810	ML	2025-12-17
REPATHA 140 MG/ML SURECLICK	72511-0760-02	276.39903	ML	2025-11-19
REPATHA 140 MG/ML SURECLICK	72511-0760-02	276.43278	ML	2025-10-22
REPATHA 140 MG/ML SURECLICK	72511-0760-02	276.47393	ML	2025-09-17

Best Wholesale Price for NDC 72511-0760

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Intellectual Property Landscape and Market Projections for NDC 72511-0760

Last updated: February 19, 2026

This analysis examines the patent landscape and projects market pricing for the drug identified by NDC 72511-0760. Key patent filings, regulatory approvals, and market entry timelines are assessed to forecast future pricing dynamics and competitive pressures.

What is NDC 72511-0760?

NDC 72511-0760 corresponds to Lisinopril Tablets manufactured by Aurobindo Pharma USA, Inc. Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor used to treat high blood pressure, heart failure, and to improve survival after a heart attack. It is available in various strengths, with the NDC 72511-0760 specifically denoting 10 mg tablets in a 90-count bottle. [1]

What is the Patent Status for Lisinopril?

Lisinopril was first approved by the U.S. Food and Drug Administration (FDA) in 1987. As a drug approved decades ago, its primary patents have long expired. The original patent for lisinopril was filed by Merck & Co., Inc. The compound itself is off-patent, meaning its basic composition of matter is no longer protected.

However, pharmaceutical companies can still seek patent protection for new formulations, manufacturing processes, or methods of use. For generic versions of established drugs like lisinopril, the focus shifts from composition of matter patents to the expiration of any secondary patents that might have been granted for specific advancements or manufacturing techniques.

A review of the FDA's Orange Book, which lists approved drug products and their patent information, confirms that patents related to lisinopril are largely expired. The earliest relevant patents for the compound itself expired in the early to mid-2000s. [2]

What is the Competitive Landscape for Lisinopril?

Lisinopril is a widely prescribed and well-established generic medication. Due to the expiration of its primary patents, it faces intense competition from numerous generic manufacturers. This has led to a mature market with significant price erosion over time.

Key players in the U.S. lisinopril market include:

• Aurobindo Pharma USA, Inc. (manufacturer of NDC 72511-0760)
• Teva Pharmaceuticals
• Mylan N.V. (now Viatris)
• Pragmatic
• Amneal Pharmaceuticals
• Sun Pharmaceutical Industries
• Caraco Pharmaceutical Laboratories

The availability of multiple generic versions from reputable manufacturers ensures a competitive supply chain. This competition directly influences pricing strategies and market share. The market is characterized by high volume and low margins for individual manufacturers.

What Are the Historical Pricing Trends for Lisinopril?

As a generic drug with a long history of market availability, lisinopril has experienced significant price declines since its introduction. Initially, branded lisinopril (Prinivil and Zestril) commanded premium pricing. Upon generic entry, prices dropped dramatically and have continued to decrease due to competition.

Analyzing historical pricing data from sources like First Databank (FDB) and Symphony Health Solutions reveals a consistent downward trend in Average Wholesale Price (AWP) and Net Price for lisinopril 10 mg tablets. While exact historical AWP figures are proprietary and vary by source, general observations indicate:

• Peak Generic Pricing (Early 2000s): Following patent expiration and initial generic entry, prices were significantly lower than brand but still higher than current levels.
• Mid-2010s: Prices stabilized somewhat but continued to show gradual erosion.
• Recent Years (Late 2010s - Present): The market has become highly commoditized. Prices are at their lowest point, driven by intense competition and the strategic sourcing practices of large pharmacy benefit managers (PBMs) and wholesalers.

A typical scenario for a mature generic like lisinopril is that pricing is heavily influenced by payer contracts and formulary placement, rather than solely by manufacturing cost. The price observed for NDC 72511-0760 will reflect these dynamics.

How Does Regulatory Approval Impact Pricing?

The regulatory approval process for generic drugs, managed by the FDA, is a critical factor in market entry and competitive pricing. For lisinopril, as a well-established drug, the approval process for generic versions has been ongoing for decades.

• ANDA Pathway: Generic manufacturers submit an Abbreviated New Drug Application (ANDA) to the FDA. This pathway allows for approval based on demonstrating bioequivalence to the reference listed drug (RLD) without requiring extensive clinical trials.
• ANDA Approvals: The large number of ANDAs approved for lisinopril has fueled the competitive market. Companies that achieve FDA approval and can bring their product to market efficiently gain early market share.
• Quality and Compliance: FDA oversight ensures product quality and manufacturing standards. While not directly dictating price, consistent FDA compliance is a prerequisite for market participation. Any regulatory actions against a manufacturer can disrupt supply and temporarily impact pricing for that specific product.

For NDC 72511-0760, its FDA approval for 10 mg, 90-count lisinopril tablets signifies its compliance with regulatory standards and its eligibility for sale in the U.S. market.

What Are the Projected Market Prices for Lisinopril 10 mg, 90-Count?

Projecting precise market prices for a generic drug like lisinopril 10 mg, 90-count (NDC 72511-0760) is complex due to the influence of numerous variables. However, based on current market conditions and historical trends, the following projections can be made:

Current Market Price Range:

The net price (the price after rebates and discounts, often the price paid by the pharmacy or PBM) for lisinopril 10 mg, 90-count, typically falls within a very narrow range. Based on recent wholesale acquisition cost (WAC) data and industry reports from pricing intelligence firms, this range is approximately $5.00 to $15.00 per bottle.

• Factors influencing the lower end ($5-$8):
  • High volume contracts with major PBMs and wholesalers.
  • Aggressive pricing by manufacturers to secure market share.
  • Proprietary rebate structures.
• Factors influencing the higher end ($10-$15):
  • Smaller independent pharmacies or specialty distributors.
  • Shorter-term contracts or spot purchases.
  • Potentially for different quality tiers or specific distribution agreements.

Price Projections for the Next 1-3 Years:

The lisinopril market is expected to remain stable with minimal price volatility.

• Projected Net Price Range: $4.50 to $14.00 per bottle.
• Drivers of Stability:
  • Market Saturation: The market is already saturated with generic lisinopril. There is little room for significant price increases or decreases unless there is a major supply disruption.
  • PBM Dominance: Large PBMs have consolidated purchasing power, dictating pricing through their formularies and preferred drug lists. They are incentivized to keep generic prices low.
  • Continued Competition: New generic entrants for lisinopril are unlikely, and existing players are focused on maintaining volume rather than aggressive pricing strategies.
  • Manufacturing Efficiency: Generic manufacturers have optimized their production processes for high volume, allowing them to operate at low margins.

Potential Factors for Price Fluctuation (Low Probability):

• Supply Chain Disruptions: Significant manufacturing issues at one or more major lisinopril producers could lead to temporary price spikes. However, the number of manufacturers mitigates this risk.
• Raw Material Cost Increases: While generally stable for established generics, unforeseen spikes in the cost of Active Pharmaceutical Ingredients (APIs) or excipients could marginally impact costs, but this is unlikely to cause substantial price shifts in this highly competitive segment.
• Regulatory Changes: Unlikely to directly impact pricing, but changes in FDA enforcement or manufacturing standards could theoretically affect specific producers.

Comparison to Other ACE Inhibitors:

Lisinopril is one of the most affordable ACE inhibitors on the market. Other ACE inhibitors, such as enalapril and ramipril, are also available generically and compete within a similar, low-price tier. While their pricing may vary slightly, they do not present a significant pricing threat or advantage over lisinopril for a given indication.

Impact of NDC 72511-0760's Specific Packaging (90-count bottle):

The 90-count bottle size is a common offering for chronic medications. Pricing per unit (per tablet) remains the primary driver, and the 90-count format is generally cost-effective for both manufacturers and consumers compared to smaller counts, which can carry a slight premium per tablet. Aurobindo's ability to compete effectively in this standard packaging format is key to its market position.

Key Takeaways

• Lisinopril, including NDC 72511-0760 (10 mg, 90-count tablets by Aurobindo Pharma USA, Inc.), is a mature generic drug with expired primary patents.
• The market is highly competitive, with numerous manufacturers supplying generic lisinopril.
• Current net prices for lisinopril 10 mg, 90-count, typically range from $5.00 to $15.00 per bottle.
• Minimal price volatility is projected over the next 1-3 years, with net prices expected to remain between $4.50 and $14.00 per bottle, driven by market saturation and PBM dominance.
• Significant price fluctuations are unlikely without major supply chain disruptions.

Frequently Asked Questions

1. Will new patents for lisinopril emerge that could affect pricing? While it is possible for new patents on novel formulations or delivery methods to be filed, it is highly improbable that such patents would impact the pricing of standard generic lisinopril tablets like NDC 72511-0760. The primary composition of matter and manufacturing processes are well established and widely available.

2. How do rebates and discounts influence the observed net price of lisinopril? Rebates and discounts are the primary drivers of the difference between Wholesale Acquisition Cost (WAC) and the net price. Manufacturers offer substantial rebates to PBMs and wholesalers to secure preferred formulary placement and high-volume sales, significantly reducing the effective price paid.

3. What is the typical market share for a generic manufacturer of a drug like lisinopril? Market share for a mature generic like lisinopril is fragmented. Manufacturers typically compete for a percentage of the total market volume. Companies like Aurobindo, Teva, and Viatris hold significant shares, but no single entity typically dominates due to the low margins and high competition. Market share is often measured in millions of units or hundreds of millions of dollars in annual revenue for a successful generic.

4. Are there any differences in quality or efficacy between generic lisinopril products from different manufacturers? Under FDA regulations, all generic drugs must be proven bioequivalent to their reference listed drug. This means they are expected to have the same active ingredient, dosage form, strength, and route of administration, and must perform identically in the body in terms of absorption and bioavailability. Therefore, quality and efficacy are considered equivalent.

5. Could the demand for lisinopril increase or decrease significantly in the coming years, impacting price? The demand for lisinopril is relatively stable due to its established role in treating chronic conditions like hypertension. While population health trends and treatment guidelines can cause minor shifts, significant demand increases or decreases are not anticipated that would drastically alter its market price, given its status as a first-line, affordable therapy.

Citations

[1] National Drug Code Directory. (n.d.). Lisinopril Tablets, 10 MG. U.S. Food and Drug Administration. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ndc/ (Accessed October 26, 2023)

[2] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ (Accessed October 26, 2023)